Effect of Clotting Time Before Centrifugation on Total Cholesterol: A Cross-Sectional Study

Fontianus Nong Melky; Nuril Sofiantin; Marisca Jenice Sanaky

doi:10.61099/jih.v2i2.250

Authors

Fontianus Nong Melky Department of Medical Laboratory Technology, Politeknik Sandi Karsa, South Sulawesi, Indonesia
Nuril Sofiantin Department of Medical Laboratory Technology, Politeknik Sandi Karsa, South Sulawesi, Indonesia
Marisca Jenice Sanaky Department of Medical Laboratory Technology, Politeknik Sandi Karsa, South Sulawesi, Indonesia

DOI:

https://doi.org/10.61099/jih.v2i2.250

Keywords:

Blood Specimen Collection, Cholesterol, Clinical Laboratory Techniques, Preanalytical Phase, Serum

Abstract

Introduction: Pre-analytical variables are a major source of laboratory testing error, with clotting time before centrifugation representing a potentially critical factor in serum-based biochemical analysis. Although total cholesterol is considered a relatively stable analyte, minor operational variations in clotting time may affect measurement accuracy. This study aimed to determine whether differences in clotting time (30 minutes versus 60 minutes) before centrifugation affect total cholesterol results under controlled laboratory conditions.

Research Methodology: A quantitative analytic study with a paired cross-sectional design was conducted in a clinical chemistry laboratory from June to August 2025. Eighteen adult participants were recruited using purposive sampling. For each participant, venous blood samples were divided into two conditions: clotting for 30 minutes and 60 minutes before centrifugation. Total serum cholesterol was measured using the enzymatic CHOD-PAP method. Data were analyzed using descriptive statistics and a Paired Sample T-Test with α = 0.05.

Results: The mean total cholesterol level after 30 minutes of clotting was 141.92 ± 18.45 mg/dL, compared to 146.33 ± 19.12 mg/dL after 60 minutes. The mean difference was 4.41 mg/dL (3.10%). Statistical analysis showed no significant difference in clotting duration between the two groups (p = 0.179).

Conclusion: Extending clotting time from 30 to 60 minutes before centrifugation does not significantly affect total cholesterol measurement. These findings support analytical stability within this interval and may inform evidence-based refinement of pre-analytical laboratory procedures.

Downloads

Download data is not yet available.

References

[1] A. D. Aulbach, D. Ennulat, and A. E. Schultze, “Chapter 14 - Clinical Pathology in Nonclinical Toxicity Studies,” pp. 343–392, 2024, doi: https://doi.org/10.1016/B978-0-323-85704-8.00008-6.

[2] S. Balasamy, R. Atchudan, S. Arya, B. M. Gunasekaran, N. Nesakumar, and A. K. Sundramoorthy, “Cortisol: Biosensing and detection strategies,” Clin. Chim. Acta, vol. 562, p. 119888, 2024, doi: https://doi.org/10.1016/j.cca.2024.119888.

[3] S. Bandyopadhyay et al., “Micronutrient Biomarker Selection and Assay Methods and Performance in Double-Blind, Randomized, Controlled Micronutrient Dose Response (MiNDR) Trials among Women of Reproductive Age and Pregnant Women in Rural Bangladesh,” Curr. Dev. Nutr., vol. 9, no. 10, p. 107546, 2025, doi: https://doi.org/10.1016/j.cdnut.2025.107546.

[4] R. M. Baral and K. P. Freeman, “Chapter 9 - Clinical Pathology,” S. E. B. T.-T. H. E. C. A. T. (Second E. Little, Ed. Philadelphia (PA): Elsevier, 2025, pp. 238-276.e9.

[5] K. Bartnik, M. Janik, M. Koba, T. Rygiel, P. Musolf, and M. Śmietana, “Biosensing solutions for protein measurement in blood-derived media: a review,” Measurement, vol. 253, p. 117756, 2025, doi: https://doi.org/10.1016/j.measurement.2025.117756.

[6] A. C. A. Dos Santos, L. Cougnaud, and D. Vuckovic, “3.19 - Sample preparation for lipidomics,” M. B. T.-C. S. and S. P. (Second E. Soylak, Ed. Oxford: Academic Press, 2025, pp. 339–366.

[7] S. A. Gouhar, Z. Y. Abd Elmageed, and S. M. El-Daly, “Chapter Two - Extracellular vesicles as dynamic biomarkers: Monitoring therapeutic responses and drug resistance in cancer,” in Circulating Biomarkers for Diagnosis, Prognosis and Treatment Response Prediction in Cancer - Part B, vol. 399, S. Spada and L. B. T.-I. R. of C. and M. B. Galluzzi, Eds. Academic Press, 2026, pp. 43–112.

[8] J. W. Guthrie, J. Siódmiak, and M. Krintus, “3.1 - General considerations when dealing with biological fluid samples,” M. B. T.-C. S. and S. P. (Second E. Soylak, Ed. Oxford: Academic Press, 2025, pp. 1–25.

[9] I. A. Hashim, “Chapter 16 - Aspects of clinical laboratory management,” I. A. B. T.-T. in C. C. Hashim, Ed. Elsevier, 2024, pp. 439–483.

[10] I. A. Hashim, “Chapter 17 - Analytical methods and special considerations,” I. A. B. T.-T. in C. C. Hashim, Ed. Elsevier, 2024, pp. 485–513.

[11] S. İncir and M. Bolayirli, “Chapter Sixteen - Polypharmacy as a reason for misinterpreting laboratory results in the elderly,” in Theoretical and Clinical Geropharmacology, vol. 104, M. C. Atayik and U. B. T.-A. in P. Çakatay, Eds. Academic Press, 2025, pp. 515–581.

[12] K. Lew, “3.2 - Blood sample collection and handling,” M. B. T.-C. S. and S. P. (Second E. Soylak, Ed. Oxford: Academic Press, 2025, pp. 26–55.

[13] C. Lorenz, A. Nevski, A. Otto, L. A. Rocha, H. Kosch, and T. Sauer, “From sample collection to lab results: Planning the supply chain of medical specimens,” Oper. Res. Data Anal. Logist., vol. 46, p. 200499, 2026, doi: https://doi.org/10.1016/j.ordal.2026.200499.

[14] D. Magro, M. Venezia, and C. Rita Balistreri, “The omics technologies and liquid biopsies: Advantages, limitations, applications,” Med. Omi., vol. 11, p. 100039, 2024, doi: https://doi.org/10.1016/j.meomic.2024.100039.

[15] M. Y. Mi and M. B. T.-R. M. in B. S. Nayor, “00050 - Novel Biomarker Discovery and Assessment,” Elsevier, 2025.

[16] M. Ness et al., “Chapter Five - Small molecule biomarkers in infectious disease,” vol. 131, G. S. B. T.-A. in C. C. Makowski, Ed. Elsevier, 2026, pp. 141–176.

[17] O. Piot, C. Gobinet, V. Untereiner, D. Saikia, and G. D. Sockalingum, “7 - Raman spectroscopy and potential clinical applications,” in Woodhead Publishing Series in Composites Science and Engineering, S. Thomas, I. Royaud, D. Chapron, and M. B. T.-R. S. A. to P. C. and N. Poncot, Eds. Woodhead Publishing, 2026, pp. 251–287.

[18] D. Sharma and C. Sims, “Chapter 21 - Clinical Pathology,” A. E. B. T.-P. of the L. R. Bradley, Ed. Academic Press, 2026, pp. 449–481.

[19] N. I. Stacy, C. Hollinger, and E. H. Hooijberg, “Chapter 4 - Introduction to Comparative Clinical Pathology,” K. A. Terio, D. McAloose, and J. B. T.-P. of W. and Z. A. (Second E. St. Leger, Eds. Academic Press, 2026, pp. 59-102.e26.

[20] P. E. Stevens et al., “KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease,” Kidney Int., vol. 105, no. 4, Supplement, pp. S117–S314, 2024, doi: https://doi.org/10.1016/j.kint.2023.10.018.

[21] S. Suprapto, “Relationship between knowledge level and contraceptive compliance among family planning acceptors: A Cross-Sectional Study,” J. Interdiscip. Heal., vol. 2, no. 1, pp. 27–34, Jan. 2026, doi: https://doi.org/10.61099/jih.v2i1.175.

[22] D. Tsikas, “1 - Principles of quantitative analysis by gas chromatography–mass spectrometry, triple quadrupole gas chromatography–mass spectrometry, and high-resolution mass spectrometry coupled to gas chromatography,” D. B. T.-Q. G. C.-M. S. in the L. S. Tsikas, Ed. Elsevier, 2026, pp. 1–174.

[23] A. Wasserkrug-Naor and L. Ramaiah, “6.22 - The Hematopoietic System: Evaluation and Data Interpretation in Nonclinical Safety Studies,” C. A. B. T.-C. T. (Fourth E. McQueen, Ed. Oxford: Elsevier, 2026, pp. 483–566.

[24] H. Wei, J. Feng, L. Zhu, Y. Wu, H. Ma, and Y. Gao, “Three cases of false decrease interference of etamsylate on biochemical laboratory tests and correction methods,” Clin. Chim. Acta, vol. 578, p. 120524, 2026, doi: https://doi.org/10.1016/j.cca.2025.120524.

[25] S. Zoroddu, A. Zinellu, C. Carru, and A. A. Mangoni, “Neopterin in inflammation and oxidative stress,” vol. 130, G. S. B. T.-A. in C. C. Makowski, Ed. Elsevier, 2026, pp. 61–98